If you need any further evidence of just how much the COVID-19 pandemic has increased the allure of biotechnology stocks, consider the little-known Chinese biotech company that saw such an influx of interest upon its recent trading debut that demand for shares exceeded the number of shares on offer by hundreds of times! For more on this particular biotech company — and how the high levels of interest in biotech could make it the “next gold mine” – CLICK HERE.
In the world of penny stocks, biotech penny stocks and energy penny stocks have been among the big movers recently – and the author of today’s article posits that “it’s got a lot to do with speculation surrounding coronavirus and the push for a turnaround in oil and gas.” She proceeds to examine three penny stocks trading under $4 that have been moving higher recently – including one up more than 300% – and whether they may be the best penny stock picks right now. For more, CLICK HERE.
In assessing the current market environment, the author of today’s article notes that “it becomes apparent that there’s an opportunity for those able to take on more risk. Within the biotech space, the effects of COVID-19 have pushed several compelling names’ share prices lower, presenting more affordable entry points.” For three of these compelling biotech stocks – all of which are trading under $4, are Buy-rated, and possess significant upside potential in the next year – CLICK HERE.
The clinical-stage biopharmaceutical company highlighted in today’s article is focused on the development of novel therapies for cardio-metabolic disease, liver disease, ophthalmic disease and cancer – and while it has yet to actually turn a profit, it generated over $103 million in revenue in 2019 (the year it IPOed), has lots of cash on hand, and perhaps most importantly, has seen significant insider buying lately. For the biotech in question – and potential action to take – CLICK HERE.
Considering the state of affairs right now, investors may be reluctant to buy expensive stocks. Thankfully, there’s penny stocks. As the author of today’s article explains, “Because they trade under $5 per share, we can tap into inexpensive stocks that have high profit potential due to coronavirus, and ride them out until the breakout ends.” For three top penny stocks to consider picking up right now – including a play on the rising demand for safe-haven gold and a play on a possible massive infrastructure spending bill – CLICK HERE.
Thanks to it ensuring a ready supply of buyers, buying stocks that are about to be included in the S&P 500 has proven to be a good strategy. On the flipside of the equation, selling stocks that are about to be kicked out of the S&P 500 is also a good idea, as those stocks are likely to only suffer further as a result of their removal. With this in mind, today’s article identifies four stocks from the battered energy sector “that are in imminent danger of being removed from the S&P 500.” For more, CLICK HERE.
This clinical-stage biopharmaceutical company focused on developing treatments for different kinds of cancers just recently launched an IPO, making it just the second IPO to launch in the U.S. since the coronavirus pandemic became the dominant issue. And while the author of today’s article acknowledges that this company “faces much of the challenges of a typical biotech IPO which means higher risk”, he argues that “there is a great deal to like about its potential and chances of success.” For more, CLICK HERE.
If exposure to cutting-edge innovations in the healthcare industry is what you’re after, consider the exchange-traded fund highlighted in today’s article, which focuses on potential medical breakthroughs from highly innovative small- and mid-cap companies that have one or more drug candidates in either Phase II or Phase III FDA clinical trials. For more on this ETF, CLICK HERE.
As testing for COVID-19 in the U.S. (or lack thereof) has been a much-discussed topic over the past month, shares of one diagnostics and pharmaceutical company with the potential to help test for the disease have been all over the place. However, as today’s article outlines, “On April 6, there was a new report of [this company] partnering with hospitals around the country for COVID-19 testing and maintain their 24-hour turnaround time. They have now tested almost 200,000 patients at a pace of 20,000 to 35,000 tests a day” – and the company’s CEO has been buying up shares on this development that could send its share price higher. For more, CLICK HERE.
While the COVID-19 pandemic is far from over, there have been some small glimmers of hope in recent days – and the market responded accordingly. Against this backdrop, Wall Street pros argue that “those ready to take on some risk have been presented with exciting opportunities” – especially within the biotech space. For three biotech stocks trading under $2 with “serious upside potential” – including one biotech firm whose upside potential is related in part to its potential treatment for COVID-19, CLICK HERE.